Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Personalized Diabetes Medicine Program, |
RCV000445445 | SCV000537020 | uncertain significance | Monogenic diabetes | 2016-06-03 | criteria provided, single submitter | research | ACMG Criteria: PP3 |
Labcorp Genetics |
RCV001857736 | SCV002280010 | likely pathogenic | not provided | 2023-10-03 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 732 of the WFS1 protein (p.Arg732Cys). This variant is present in population databases (rs71526458, gnomAD 0.02%). This missense change has been observed in individual(s) with autosomal recessive Wolfram syndrome and/or clinical features of WFS1-related conditions (PMID: 32179840, 34404380, 34573359, 35469785). ClinVar contains an entry for this variant (Variation ID: 215396). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt WFS1 protein function. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
Fulgent Genetics, |
RCV002500616 | SCV002814092 | uncertain significance | Cataract 41; Wolfram syndrome 1; Autosomal dominant nonsyndromic hearing loss 6; Type 2 diabetes mellitus; Wolfram-like syndrome | 2022-03-24 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV001857736 | SCV004226102 | likely pathogenic | not provided | 2023-03-23 | criteria provided, single submitter | clinical testing | PP3, PM2, PM3_supporting, PS4_moderate |
Genomics England Pilot Project, |
RCV001542532 | SCV001760142 | pathogenic | Type 2 diabetes mellitus | no assertion criteria provided | clinical testing |